MedTrace Logo

Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia

NCT06647888 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 12000

Last updated 2025-01-23

No results posted yet for this study

Summary

This observational study is a non-interventional, multi-center, prospective observational study aimed at tracking the efficacy and safety of Envlo or Envlomet SR tablets for 24 weeks in patients with type 2 diabetes and hypertension or dyslipidemia who are currently taking or are scheduled to take Envlo or Envlomet SR tablets in an actual clinical setting.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Envlo Tablet

Envlo Tab. 0.3mg

DRUG

Envlomet SR Tablet

Envlomet SR Tablet 0.3/ Metformin1,000mg

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Principal Investigators

  • Sang Hoon Moon · Happy Yonsei Family Medicine Clinic

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-03
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06647888 on ClinicalTrials.gov